Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GFB 024

Next Previous
Drug Profile

GFB 024

Alternative Names: GFB-024

Latest Information Update: 28 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Developer Goldfinch Bio
  • Class Monoclonal antibodies; Urologics
  • Mechanism of Action Cannabinoid receptor CB1 inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Diabetic nephropathies; Focal segmental glomerulosclerosis

Most Recent Events

  • 28 Jun 2024 No recent reports of development identified for phase-I development in Diabetic-nephropathies(In volunteers) in USA (Parenteral)
  • 03 Jun 2022 Interim pharmacokinetics and adverse events data from a phase I trial in diabetic nephropathies presented at the 82nd Annual Scientific Sessions of the American Diabetes Association (ADA-2022)
  • 08 Feb 2022 Goldfinch Bio completes a first-in-human phase I trial in Diabetic nephropathies (In volunteers) in USA (Parenteral) (NCT04880291)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top